Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. Th… Read more
Propanc Biopharma, Inc. Common Stock (PPCB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.096x
Based on the latest financial reports, Propanc Biopharma, Inc. Common Stock (PPCB) has a cash flow conversion efficiency ratio of -0.096x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-999.14K) by net assets ($10.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Propanc Biopharma, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Propanc Biopharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Propanc Biopharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Propanc Biopharma, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Braille Energy Systems Inc
V:BES
|
-0.049x |
|
ReShape Lifesciences Inc
NASDAQ:RSLS
|
-0.771x |
|
Fragbite Group AB
ST:FRAG
|
-0.211x |
|
L&P Global Berhad
KLSE:0268
|
0.032x |
|
Ateliers Mecaniques D’Indonesie Tbk PT
JK:AMIN
|
0.114x |
|
Braster S.A.
WAR:BRA
|
-0.048x |
|
Golden Sun Education Group Ltd
NASDAQ:GSUN
|
-0.091x |
|
RALPH LAUREN-A
BE:PRL
|
0.040x |
Annual Cash Flow Conversion Efficiency for Propanc Biopharma, Inc. Common Stock (2010–2025)
The table below shows the annual cash flow conversion efficiency of Propanc Biopharma, Inc. Common Stock from 2010 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $13.91 Million | $-405.17K | -0.029x | -111.77% |
| 2024-06-30 | $-3.78 Million | $-935.12K | 0.247x | -30.21% |
| 2023-06-30 | $-3.12 Million | $-1.11 Million | 0.355x | -25.36% |
| 2022-06-30 | $-3.02 Million | $-1.44 Million | 0.475x | +27.23% |
| 2021-06-30 | $-3.07 Million | $-1.15 Million | 0.373x | -26.50% |
| 2020-06-30 | $-3.64 Million | $-1.85 Million | 0.508x | +6.05% |
| 2019-06-30 | $-4.30 Million | $-2.06 Million | 0.479x | +48.50% |
| 2018-06-30 | $-6.75 Million | $-2.18 Million | 0.323x | -18.43% |
| 2017-06-30 | $-5.44 Million | $-2.15 Million | 0.395x | -78.87% |
| 2016-06-30 | $-2.57 Million | $-4.80 Million | 1.871x | +300.52% |
| 2015-06-30 | $-3.05 Million | $-1.43 Million | 0.467x | +190.54% |
| 2014-06-30 | $-1.41 Million | $-226.44K | 0.161x | -0.95% |
| 2013-06-30 | $-792.48K | $-128.65K | 0.162x | -48.72% |
| 2012-06-30 | $-537.92K | $-170.28K | 0.317x | +338.36% |
| 2011-06-30 | $10.51 Million | $-1.40 Million | -0.133x | -112.96% |
| 2010-06-30 | $-186.90K | $-191.51K | 1.025x | -- |